Skip to Main Content Skip to Site Map Skip to Accessibility Statement

Not Recommended Technology Appraisals (TAs)

Technology appraisals which have not been approved by the National Institute for Health and Care Excellence (NICE) and endorsed by the Department of Health as applicable to Northern Ireland are referred to as ‘Not Recommended’.

In most instances, a technology will not be recommended if there is a lack of evidence for its clinical effectiveness or if the technology is not considered to be a cost-effective use of resources, compared with current practice. For these technology appraisals, organisations should ensure that no patient commences treatment, however, in line with policy the Health and Social Care Board will consider Individual Funding Requests for the use of these treatments for the relevant indication on the grounds of clinical exceptionality as defined in the [wpfilebase tag=fileurl id=2516 linktext=’HSCB/PHA Arrangements for the consideration of request for care/and or treatment on behalf of individual patients’ /].

Not Recommended Technology Appraisals (TAs) are listed below in alphanumerical order.

Title and link to NICE website
Date issued by DoH
TA909 Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer 14-09-2023
TA900 Tixagevimab plus cilgavimab for preventing COVID-19 14-09-2023
TA894 Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma 14-09-2023
TA892 Mosunetuzumab for treating relapsed or refractory follicular lymphoma 14-09-2023
TA883 Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma 14-09-2023
TA881 Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments 14-09-2023
TA854 Esketamine nasal spray for treatment-resistant depression 21-04-2023
TA850 Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy 21-04-2023
TA831 Reviewed by TA887 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer 21-04-2023
TA812 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer 01-09-2022
TA795 Review of TA491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia (review of TA491) 01-09-2022
TA777 Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea 01-09-2022
TA776 Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea 01-09-2022
TA724 Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer 21-01-2022
TA721 Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer 01-09-2022
TA706 Ozanimod for treating relapsing–remitting multiple sclerosis 20-12-2021
TA696 Tafamidis for treating transthyretin amyloidosis with cardiomyopathy 08-06-2021
TA692 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (review of TA519) 01-02-2022
TA669 Reviewed by TA852 Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies 16-04-2021
TA650 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma 02-11-2020
TA621 Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer 28-02-2019
TA613 Part Review of TA301 Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (part review of TA301) 03-01-2020
TA604 Idelalisib for treating refractory follicular lymphoma 24-10-2019
TA580 Enzalutamide for hormone-relapsed non-metastatic prostate cancer 05-07-2019
TA556 Darvadstrocel for treating complex perianal fistulas in Crohn’s disease. 05-02-2019
TA550 Vandetanib for treating medullary thyroid cancer 10-01-2019
TA546 Padeliporfin for untreated localised prostate cancer. 31-12-2018
TA532 Cenegermin for treating neurotrophic keratitis. 26-10-2018
TA530 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy. 26-10-2018
TA515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (review of TA250). 22-05-2018
TA514 Regorafenib for previously treated advanced hepatocellular carcinoma 21-05-2018
TA506 Lesinurad for treating chronic hyperuricaemia in people with gout 27-03-2018
TA503 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer 23-03-2018
TA501 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer. 08-06-2018
TA494 Naltrexone–bupropion for managing overweight and obesity 04-01-2018
TA489 Vismodegib for treating basal cell carcinoma 14-12-2017
TA440 Pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine 12-07-2017
TA 411 Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma 29-11-2016
TA 403 Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer 16-09-2016
TA 399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts 03-06-2016
TA 398 Lumacaftor and ivacaftor combination therapy for treating cystic fibrosis homozygous for the F508del mutation 03-06-2016
TA 378 Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after chemotherapy 03-06-2016
TA 371 Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane 11-01-2016
TA 368 Apremilast for treating moderate to severe plaque psoriasis 23-12-2015
TA 360 Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer 23-11-2015
TA 355 Edoxaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation 20-01-2016
TA 338 Pomalidomide for treating relapsed and refractory multiple myeloma previously treated with both lenalidomide and bortezomib 26-05-2015
TA 332 Sipuleucel-T for the first line treatment of metastatic hormone relapsed prostate cancer 09-03-2015
TA 309 Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer 23-05-2014
TA 307 Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaplatin-based chemotherapy. 07-05-2014
TA 299 Bosutinib for previously treated chronic myeloid leukaemia 07-01-2014
TA 296 Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene 22-10-2013
TA 295 Everolimus in combination with an aromatase inhibitor for the treatment of HER2 negative, oestrogen receptor positive locally advanced or metastatic breast cancer after prior endocrine therapy. 24-09-2013
TA 291 Pegloticase for treating severe debilitating chronic tophaceous gout 26-07-2013
TA 289 Ruxolitinib for disease-related splenomegaly or symptoms in adult with myelofibrosis  26-07-2013
TA 285 Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer 27-06-2013
TA 284 Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer 27-06-2013
TA 272 Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract 28-02-2013
TA 271 Diabetic macular oedema – fluocinolone acetonide intravitreal implant 28-02-2013
TA 263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer 20-12-2012
TA 257 Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 13-09-2012
TA 255 Cabazitaxel for the second-line treatment of hormone refractory, metastatic prostate cancer 13-09-2012
TA 250 Eribulin- locally advanced or metastatic breast cancer 13-09-2012
TA 242 Colorectal cancer (metastatic) 2nd line- cetuximab, bevacizumab and panitumumab (review) 13-09-2012
TA 239 Breast Cancer (Metastic) – Fultvestrant 13-09-2012
TA 237 Macular oedema (diabetic) – ranibizumab 13-09-2012